Clinical Trials on Hepatic Malignancies in South Africa

Total 148 results

Pfizer

Completed

Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction

Mild Hepatic Dysfunction | Moderate Hepatic Dysfunction

South Africa
Convergence Pharmaceuticals

Completed

Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia

Post-herpetic Neuralgia

South Africa
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

Alcoholism | Hepatic Cirrhosis

Germany, Belgium, United States, South Africa
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Advanced Malignancies

Australia, China
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies

Peritoneal Malignancies

Australia
Cycle Pharmaceuticals Ltd.
Parexel

Completed

Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride

Acute Intermittent Porphyria | Anti-Psychotic | Management of Manifestations of Psychotic Disorders | Treatment of Schizophrenia | Control Nausea and Vomiting | Relief of Restlessness and Apprehension Before Surgery | Adjunct in the Treatment of Tetanus | Control Manifestations of the Manic Type... and other conditions

South Africa
BeiGene

Completed

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

B-cell Malignancies

Australia
Eucure (Beijing) Biopharma Co., Ltd

Completed

A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

Australia
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 in Adult Patients With Advanced Malignancies

Cancer, Advanced Malignancies

Canada, United States
Pfizer

Completed

A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Insufficiency

United States
Incyte Corporation

Completed

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

B-Cell Malignancies

United States
Pfizer

Completed

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

Healthy | Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction

United States
Novartis Pharmaceuticals

Completed

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

Hepatic Impairment

United States
Medical University of South Carolina
Emory University

Completed

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant

Liver Failure

United States
Ono Pharma USA Inc
Ono Pharmaceutical Co. Ltd

Completed

An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment

Healthy | Hepatic Impairment

United States
Medical University of South Carolina

Terminated

Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)

Hematological Malignancies

United States
Alnylam Pharmaceuticals

Completed

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Acute Hepatic Porphyria

United States, Belgium, Bulgaria, France, Italy, Mexico, Spain, Taiwan, United Kingdom, Netherlands, Korea, Republic of, Switzerland, Czechia, Poland, Finland, Australia, Germany, Israel, Norway, South Africa
BeiGene

Recruiting

Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies

Mature B-Cell Malignancies

United States, Italy, Australia, New Zealand, Spain, Germany, United Kingdom
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Part 1：r/r B-cell Malignancies | Part 2：B-cell Malignancies

United States, Poland, Israel, Ukraine
BeiGene

Completed

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

B-cell Malignancies

United States, Korea, Republic of, Australia, New Zealand, United Kingdom, Italy
Mateon Therapeutics

Completed

Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden (OXi4503)

Neoplasm Metastasis

Australia
Hutchison Medipharma Limited
Iqvia Pty Ltd

Unknown

A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies

Hematologic Malignancies

Australia
University of Athens

Recruiting

Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock (CORVICTES-ΥΜ)

Septic Shock

Greece
Regeneron Pharmaceuticals
Sanofi

Completed

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Malignancies

United States, Korea, Republic of, Australia, Ireland, United Kingdom
University of Texas Southwestern Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Terminated

Study of N-Acetylcysteine in Acute Liver Failure (ALF) (ONAC)

Acute Liver Failure | Fulminant Hepatic Failure

United States
William Lee
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

A Multi-Center Trial to Study Acute Liver Failure in Adults (ALFSG)

Acute Liver Failure | Fulminant Hepatic Failure | Acute Liver Injury

United States, Canada
The Hospital for Sick Children
Bristol-Myers Squibb

Terminated

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

Refractory or Recurrent Hypermutated Malignancies | Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients

United States, France, Canada, Australia, Israel
BeiGene

Completed

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

Australia, Korea, Republic of, United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas

Solid Malignancies or Lymphomas

Australia
Bausch Health Americas, Inc.

Completed

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE) (OHE)

Overt Hepatic Encephalopathy

United States
Yonsei University

Completed

The Intraoperative Physiologic Changes of Patients Under Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Prospective Observational Study

Peritoneal Surface Malignancies

Korea, Republic of
iN Therapeutics Co., Ltd.

Recruiting

A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.

Pain | Osteoarthritis | Chronic Pain | Neuropathic Pain | Post Herpetic Neuralgia

Australia
Incyte Corporation

Terminated

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Metastatic Cancer | Solid Tumors | Advanced Malignancies

United States
Medical University of South Carolina

Completed

Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial). (ACCESS)

Hepatic Carcinoma | Chemoembolizaton | Transarterial Embolization

United States
Ocera Therapeutics, Inc.

Completed

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE) (STOP-HE)

Hepatic Encephalopathy | Acute Episode of Overt Hepatic Encephalopathy

Belgium, Germany, Italy, Spain, United States, France, Austria, Russian Federation, Czechia, Australia, Hungary, Israel, Netherlands, Bulgaria, Estonia, Denmark, New Zealand
Ocera Therapeutics

Completed

AST-120 Used to Treat Mild Hepatic Encephalopathy (ASTUTE)

Mild Hepatic Encephalopathy

United States
The George Institute

Completed

Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS (FluDReSS)

Septic Shock | Critically Ill

Australia
University of Athens
Naval Hospital, Athens; General Hospital of Nikaia "Saint Panteleimon"

Recruiting

Vitamin C, Hydrocortisone and Thiamine for Septic Shock (CORVICTES)

Shock, Septic

Greece
Exact Sciences Corporation

Terminated

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies

Hematologic Malignancy

United States
Arcus Biosciences, Inc.
Gilead Sciences

Recruiting

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

Gastrointestinal Tract Malignancies

United States, Korea, Republic of, France, Serbia, Canada
Accenture

Completed

Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

Hematologic Malignancies

Korea, Republic of, Australia, Canada
Bausch Health Americas, Inc.

Active, not recruiting

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3131)

Hepatic Encephalopathy

United States, Australia, Canada, Puerto Rico
Pfizer

Terminated

LGX818 for Patients With BRAFV600 Mutated Tumors (SIGNATURE)

Solid Tumor | Hematologic Malignancies

United States
AstraZeneca

Completed

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)

Advanced Solid Malignancies

United States, Germany, Italy, United Kingdom, Canada, France, Korea, Republic of, Netherlands
The George Institute for Global Health, Australia

Completed

Days Alive and Out of Hospital for Patients With Sepsis

Sepsis | Septic Shock

Australia
Albert Einstein Healthcare Network
Patient-Centered Outcomes Research Institute

Recruiting

Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD) (PAL-LIVER)

End Stage Liver Disease

United States
Axcella Health, Inc

Terminated

Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy (EMMPOWER)

Hepatic Encephalopathy

Spain, United States, Canada, Italy, Hungary, Poland, United Kingdom
Novartis Pharmaceuticals

Terminated

BGJ398 for Patients With Tumors With FGFR Genetic Alterations (CBGJ398XUS04)

Solid Tumor | Hematologic Malignancies

United States
Lateral Pharma Pty Ltd

Completed

Oral LAT8881 in Neuropathic Pain

Neuropathic Pain | Diabetic Peripheral Neuropathy (DPN) | Post Herpetic Neuralgia (PHN)

Australia, United Kingdom
Genfleet Therapeutics (Shanghai) Inc.
Sellas Life Sciences Group

Recruiting

A Study of GFH009 in Patients With Hematologic Malignancies

Hematologic Malignancies

China, United States

Clinical Trials on Hepatic Malignancies in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations